OSE Immunotherapeutics has filed a patent for IL-7 variants and bifunctional molecules containing them, along with their potential uses. The details of the patent claim have been canceled. GlobalData’s report on OSE Immunotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights OSE Immunotherapeutics SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on OSE Immunotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. OSE Immunotherapeutics's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Il-7 variants and their uses

Source: United States Patent and Trademark Office (USPTO). Credit: OSE Immunotherapeutics SA

A recently filed patent (Publication Number: US20230303648A1) describes a bifunctional molecule that combines an interleukin 7 (IL-7) variant with a binding moiety. The molecule is designed to specifically target immune cells and has improved pharmacokinetics compared to existing molecules. The IL-7 variant has at least 75% identity with a wild type human IL-7 (wth-IL-7) and includes specific amino acid mutations that reduce its affinity for the IL-7 receptor (IL-7R). The binding moiety, which can be an antibody or antigen fragment, is fused to the IL-7 variant using a peptide linker.

The IL-7 variant can have various amino acid substitutions, including W142H, W142F, W142Y, C2S-C141S and C47S-C92S, C2S-C141S and C34S-C129S, C47S-C92S and C34S-C129S, D74E, D74Q, D74N, Q11E, Y12F, M17L, Q22E, and/or K81R. These substitutions reduce the affinity of the IL-7 variant for IL-7R and improve the pharmacokinetics of the bifunctional molecule. The binding moiety can be a heavy chain constant domain or Fc domain of a human IgG1 or IgG4, with specific substitutions to enhance its function.

The molecule targets immune cells, specifically T cells or exhausted T cells, by binding to targets expressed on their surface. These targets include PD-1, CD28, CD80, CTLA-4, BTLA, TIGIT, CD160, CD40L, ICOS, CD27, OX40, 4-1BB, GITR, HVEM, Tim-1, LFA-1, TIM3, CD39, CD30, NKG2D, LAG3, B7-1, 2B4, DR3, CD101, CD44, SIRPG, CD28H, CD38, CXCR5, CD3, PDL2, CD4, and CD8.

The patent also covers isolated nucleic acid sequences encoding the bifunctional molecule, host cells containing these sequences, pharmaceutical compositions comprising the molecule and a pharmaceutically acceptable carrier, and a method of treating cancer or infectious diseases by administering the molecule or composition to a subject with cancer or an infectious disease.

Overall, this patent describes a novel bifunctional molecule that combines an IL-7 variant with a binding moiety to target immune cells. The molecule has improved pharmacokinetics and can be used for the treatment of cancer and infectious diseases.

To know more about GlobalData’s detailed insights on OSE Immunotherapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies